- Home
- CLM vs LSBPW Comparison
CLM vs LSBPW Comparison
Compare CLM & LSBPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLM
- LSBPW
- Stock Information
- Founded
- CLM 1987
- LSBPW N/A
- Country
- CLM United States
- LSBPW China
- Employees
- CLM N/A
- LSBPW 758
- Industry
- CLM Finance/Investors Services
- LSBPW Biotechnology: Pharmaceutical Preparations
- Sector
- CLM Finance
- LSBPW Health Care
- Exchange
- CLM Nasdaq
- LSBPW Nasdaq
- Market Cap
- CLM N/A
- LSBPW N/A
- IPO Year
- CLM N/A
- LSBPW N/A
- Fundamental
- Price
- CLM $8.79
- LSBPW $0.04
- Analyst Decision
- CLM
- LSBPW
- Analyst Count
- CLM 0
- LSBPW 0
- Target Price
- CLM N/A
- LSBPW N/A
- AVG Volume (30 Days)
- CLM 1.4M
- LSBPW N/A
- Earning Date
- CLM 01-01-0001
- LSBPW N/A
- Dividend Yield
- CLM 18.74%
- LSBPW N/A
- EPS Growth
- CLM N/A
- LSBPW N/A
- EPS
- CLM N/A
- LSBPW N/A
- Revenue
- CLM N/A
- LSBPW N/A
- Revenue This Year
- CLM N/A
- LSBPW N/A
- Revenue Next Year
- CLM N/A
- LSBPW N/A
- P/E Ratio
- CLM N/A
- LSBPW N/A
- Revenue Growth
- CLM N/A
- LSBPW N/A
- 52 Week Low
- CLM $6.25
- LSBPW N/A
- 52 Week High
- CLM $8.84
- LSBPW N/A
- Technical
- Relative Strength Index (RSI)
- CLM 70.40
- LSBPW N/A
- Support Level
- CLM $8.53
- LSBPW N/A
- Resistance Level
- CLM $9.00
- LSBPW N/A
- Average True Range (ATR)
- CLM 0.12
- LSBPW 0.00
- MACD
- CLM 0.00
- LSBPW 0.00
- Stochastic Oscillator
- CLM 76.67
- LSBPW 0.00
About LSBPW LakeShore Biopharma Co. Ltd
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.